Literature DB >> 30775128

Percutaneous Drilling for Early-Stage Osteonecrosis About the Ankle.

Bradley M Lamm1, Kimona Issa1, Bhaveen H Kapadia1, Qais Naziri2, Lynne C Jones3, Michael A Mont1.   

Abstract

INTRODUCTION: The mid-term clinical, patient-reported, and radiographic outcomes of percutaneous drilling to treat early-stage osteonecrosis (without joint collapse) of the distal part of the tibia or of the talus are promising. STEP 1 PREOPERATIVE PLANNING FOR A LATERAL TALAR LESION: Obtain anteroposterior and lateral ankle radiographs as well as magnetic resonance imaging (MRI) studies of the ankle to evaluate the stage of the osteonecrotic disease. STEP 2 PERCUTANEOUS PIN INSERTION LATERAL TALAR LESION: Insert a 1.8-mm Steinmann pin or Ilizarov wire percutaneously under biplanar fluoroscopic visualization. STEP 3 PERCUTANEOUS DRILLING: Make one, two, or three passes with a 3.2-mm cannulated drill bit over the pin into the lesion(s). STEP 4 BACKFILLING THE BONE TUNNEL OPTIONAL: Infiltrate the defect with demineralized bone matrix to backfill the drill track and the deep necrotic bone defect. STEP 5 POSTOPERATIVE MANAGEMENT: The patient bears weight as tolerated in a removable short leg rigid boot for the first four weeks and avoids high-impact activities for at least ten months.
RESULTS: In our study, there were significant improvements in the mean American Orthopaedic Foot & Ankle Society (AOFAS) ankle-hindfoot score (p = 0.001), University of California Los Angeles (UCLA) activity score (p = 0.025), and visual analog scale (VAS) pain score (p = 0.001) at a mean of five years (range, two to nine years) postoperatively.IndicationsContraindicationsPitfalls & Challenges.

Entities:  

Year:  2014        PMID: 30775128      PMCID: PMC6355047          DOI: 10.2106/JBJS.ST.M.00069

Source DB:  PubMed          Journal:  JBJS Essent Surg Tech        ISSN: 2160-2204


  20 in total

Review 1.  Avascular necrosis of the talus.

Authors:  Robert S Adelaar; James R Madrian
Journal:  Orthop Clin North Am       Date:  2004-07       Impact factor: 2.472

2.  Retrograde intramedullary nail arthrodesis for avascular necrosis of the talus.

Authors:  J George Devries; Terrence M Philbin; Christopher F Hyer
Journal:  Foot Ankle Int       Date:  2010-11       Impact factor: 2.827

Review 3.  Avascular necrosis of the talus: current treatment options.

Authors:  Frank Horst; Brett J Gilbert; James A Nunley
Journal:  Foot Ankle Clin       Date:  2004-12       Impact factor: 1.653

4.  Percutaneous drilling for the treatment of secondary osteonecrosis of the knee.

Authors:  G Marulanda; T M Seyler; N H Sheikh; M A Mont
Journal:  J Bone Joint Surg Br       Date:  2006-06

Review 5.  Atraumatic osteonecrosis of the distal radius and ulna: case series and review.

Authors:  D Alex Stroh; Dawn M LaPorte; David A Marker; Aaron J Johnson; Michael A Mont
Journal:  J Hand Surg Am       Date:  2011-11-05       Impact factor: 2.230

6.  Atraumatic osteonecrosis of the humeral head.

Authors:  M A Mont; R K Payman; D M Laporte; M Petri; L C Jones; D S Hungerford
Journal:  J Rheumatol       Date:  2000-07       Impact factor: 4.666

7.  Retrograde drilling of osteochondral lesions of the medial talar dome.

Authors:  W S Taranow; G A Bisignani; J D Towers; S F Conti
Journal:  Foot Ankle Int       Date:  1999-08       Impact factor: 2.827

8.  Percutaneous drilling for the treatment of atraumatic osteonecrosis of the ankle.

Authors:  German A Marulanda; Mike S McGrath; Slif D Ulrich; Thorsten M Seyler; Ronald E Delanois; Michael A Mont
Journal:  J Foot Ankle Surg       Date:  2010 Jan-Feb       Impact factor: 1.286

Review 9.  Nontraumatic osteonecrosis of the femoral head: ten years later.

Authors:  Michael A Mont; Lynne C Jones; David S Hungerford
Journal:  J Bone Joint Surg Am       Date:  2006-05       Impact factor: 5.284

10.  Core decompression of the femoral head for osteonecrosis using percutaneous multiple small-diameter drilling.

Authors:  Michael A Mont; Phillip S Ragland; Gracia Etienne
Journal:  Clin Orthop Relat Res       Date:  2004-12       Impact factor: 4.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.